Sotera Health posts 4.4% revenue growth in Q3 2026, raises full-year outlook with strong segment gains.

Sotera Health reported a 4.4% increase in net revenues for Q3 2026, driven by strong growth in its Sterigenics and Nelson Labs segments. The company achieved a 12% rise in adjusted earnings per share and improved its adjusted EBITDA margin by nearly 100 basis points. Despite a decline in Nordion revenues due to timing of cobalt-60 harvests, overall performance was solid, leading Sotera to reaffirm its full-year 2026 revenue growth forecast of 5.25% to 6.75%. The company also improved its net leverage ratio to 2.9x and received a credit rating upgrade, signaling financial strength going forward.

Sotera Health's stock is trading at USD 17.69 on Pluang as of Nov 03, 2026 19:13 WIB, slightly below its 52-week high of USD 19.57 and well above the 52-week low of USD 13.13. Despite a minor 0.20% decline in the last day, investor interest remains strong with 100% buy orders recorded and a market cap of $5.06 billion. This trading activity contrasts with the company's solid revenue and earnings growth reported for Q3 2026.